GENE ONLINE|News &
Opinion
Blog

Breast Cancer
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
2023-03-28
Menarini’s Oral SERD Gains First-Ever FDA Approval for Breast Cancer
2023-01-30
Action Date Set for Gilead Sciences’ HR+/HER2- breast cancer sBLA
2022-10-11
Roche’s Newly Approved Companion Diagnostic May Open Treatment Options for HER2-low Patients
2022-10-06
AstraZeneca and Merck’s HER2-negative Breast Cancer Treatment Wins Yet Another Approval
2022-08-25
Sanofi Abandons SERD Candidate After Second Breast Cancer Clinical Trial Blow
2022-08-18
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
First Targeted Therapy for HER2-Low Breast Cancer Approved by FDA
2022-08-05
Amazon, Fred Hutchinson Begin Human Trial for Cancer Vaccine
2022-07-14
Organon Licenses Biosimilars From Shanghai’s Henlius For $103 Million
2022-06-14
Everest Medicines Secures Breast Cancer Drug Approval in China
2022-06-13
ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics
2022-06-07
Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug
2022-06-06
1 2 3 4
LATEST
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
2024-02-21
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
2024-02-19
Degrader-Antibody Conjugates (DACs): Targeted Degradation for Therapeutics
2024-02-19
EVENT
Scroll to Top